RESEARCH ON THE SITUATION OF ANXIETY DISORDERS, DEPRESSION, STRESS AND TREATMENT RESULTS OF ADULT ATOPIC DERMATITIS PATIENTS AT CAN THO HOSPITAL OF DERMATO-VENEREOLOGY IN 2023
Main Article Content
Abstract
Background: Atopic dermatitis is the most prevalent chronic skin condition. While not lifethreatening, it significantly impacts mental health, with increased risks of anxiety and depression commonly observed in chronic diseases, including atopic dermatitis. Objectives: to determine the prevalence of anxiety, depression, stress, and related factors in adult patients with atopic dermatitis, as well as describe treatment results at Can Tho Hospital of Dermato-Venereology in 2023. Materials and method: A cross-sectional study of 115 adult patients with atopic dermatitis over 4 weeks, in which patients were assessed for anxiety disorders, depression, and stress using the DASS21 scale. Results: The majority of patients experienced mild anxiety (47%), mild stress (47%), and mild depression (21.7%). There was a statistically significant association between atopic dermatitis with pruritus symptoms, insomnia, or moderate-to-severe disease severity and the prevalence of anxiety disorders, depression, and stress (p<0.05). After four weeks of treatment, the mean SCORAD score difference was 10.94±7.19 compared to baseline (p<0.001), with the majority (75.7%) achieving moderate-to-good treatment outcomes. The prevalence of anxiety disorders, depression, and stress remained higher in the poor treatment outcome group compared to the moderate-to-good outcome group (p<0.001). Conclusion: The prevalence of stress, anxiety, and depression disorders was relatively high among patients with atopic dermatitis and showed a statistically significant association with pruritus symptoms, insomnia, and disease severity. After treatment, the mean SCORAD score difference was 10.94±7.19 compared to baseline (p<0.001), and the prevalence of stress, anxiety, and depression disorders improved.
Keywords
atopic dermatitis, anxiety disorder, depression, stress
Article Details
References
2. Trần Thị Hưng An. Kết quả điều trị tại chỗ viêm da cơ địa mạn tính bằng E-PSORA (polyhydroxy acid, jojoba oil, vitamin e) tại Bệnh viện Da liễu Thành phố Cần Thơ và bệnh viện Trường đại học Y Dược Cần Thơ năm 2020-2022. Tạp chí Y Dược học Cần Thơ. 2022. 50, 136-143, https://doi.org/10.58490/ctump.2022i50.135.
3. Lưu Nguyễn Anh Thư, Nguyễn Tất Thắng. Nồng độ Interleukin-2 huyết thanh của bệnh nhân viêm da cơ địa tại Bệnh viện Da liễu thành phố Hồ Chí Minh. Tạp chí Y học thành phố Hồ Chí Minh. 2014. 18(1), 117-124.
4. Nguyễn Thị Kim Cúc, Huỳnh Văn Bá. Nghiên cứu đặc điểm lâm sàng, mức độ lo âu và đánh giá kết quả điều trị tại chỗ viêm da cơ địa mạn bằng e-psora tại Thành phố Cần Thơ năm 2022-2023. Trường Đại học Y Dược Cần Thơ. 2023.
5. Tsintsadze N, Beridze L, Tsintsadze N, Krichun Y, Tsivadze N, Tsintsadze M. Psychosomatic aspects in patients with dermatologic diseases. Georgian Med News. 2015; (243):70-5, PMID: 26087735.
6. Phạm Thị Minh Phương, Vũ Thanh Tùng, Trịnh Minh Trang. Hiệu quả của chất làm ẩm da Ceracalm A.D trên bệnh nhân viêm da cơ địa mức độ nhẹ, trung bình tại Bệnh viện Da Liễu Trung Ương, Da liễu học. 2018. Số 26.
7. Koh MJ, Giam YC, Liew HM, Foong AY, Chong JH, Wong SMY, Tang MBY, Ho MSL, Tan LS, Mason JM, Cork MJ. Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer. Dermatol Ther (Heidelb). 2017. 7(3):383-393, doi: 10.1007/s13555-017-0186-1.
8. Hon KL, Kung JSC, Ng WGG, Leung TF. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. Drugs Context. 2018 Apr 17. 7:212530, doi: 10.7573/dic.212530.
9. Mina S, Jabeen M, Singh S, Verma R. Gender differences in depression and anxiety among atopic dermatitis patients. Indian J Dermatol. 2015 Mar-Apr. 60(2), 211, doi: 10.4103/0019-5154.152564.
10. Simpson E, L. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016. 74(3), pp. 491-498, https://doi.org/10.1016/j.jaad.2015.10.043.
11. Duran, Songül, and Emine Atar. Determination of depression, anxiety and stress (DAS) levels in patients with atopic dermatitis: a case-control study. Psychology, Health & Medicine. 2020. 25 (9),1153-1163, https://doi.org/10.1080/13548506.2019.1710545.
12. Ahmed AE, Al-Dahmash AM, Al-Boqami QT, Al-Tebainawi YF. Depression, Anxiety and Stress among Saudi Arabian Dermatology Patients: Cross-sectional study. Sultan Qaboos Univ Med J. 2016. 16(2):e217-23, doi: 10.18295/squmj.2016.16.02.013.
13. Park H, Kim K. Association of Perceived Stress with Atopic Dermatitis in Adults: A PopulationBased Study in Korea. Int J Environ Res Public Health. 2016. 13(8):760, doi:
10.3390/ijerph13080760.
14. Schonmann Y et al. Atopic Eczema in Adulthood and Risk of Depression and Anxiety: A Population-Based Cohort Study. The journal of allergy and clinical immunology. In practic. 2020. 8(1), pp. 248–257, https://doi.org/10.1016/j.jaip.2019.08.030.
15. Cork M et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment. 2019. https://doi.org/10.1080/09546634.2019.1612836.